Sheena Jonathan, a co-founder of Natera, Inc., has sold shares in the company to meet tax obligations associated with the vesting of restricted stock units (RSUs). This recent transaction, filed on November 4, 2026, is significant as it highlights the ongoing financial maneuvers of executives within the medical laboratories sector.

Natera, Inc. is a prominent player in the medical laboratories industry, focusing on genetic testing and diagnostics. The company is incorporated in Delaware and has its business address in Austin, Texas. It operates under the Central Index Key (CIK) 0001604821 and is listed under the standard industrial classification of services related to medical laboratories.

According to the SEC filing, Jonathan sold a total of 112 shares on November 2, 2026. The sales were executed at prices of $388.20 and $400.29 per share, respectively. Following these transactions, Jonathan retains ownership of 217,574 shares directly. The filing notes that these sales were made to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs.

The filing further specifies that Jonathan's shares held through trusts are not directly owned by her, as she disclaims beneficial ownership over these securities. This highlights the complexities involved in executive shareholding structures and tax obligations in publicly traded companies.

This transaction may impact Natera's executive landscape and investor perception as it navigates the competitive medical laboratories sector. The filing does not specify what actions may follow this sale, leaving questions about future share management and executive transactions.